Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06079359 · ClinicalTrials.gov registry record · Phase 3

Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP

A Phase 3 study of Hypophosphatasia, sponsored by Alexion Pharmaceuticals.

Active
Registry status
Phase 3
Development phase
30
Enrollment target
20
Study locations

NCT06079359 is a Phase 3 study of Hypophosphatasia that is active but no longer recruiting, run by Alexion Pharmaceuticals. The registered enrollment target is 30 participants, below the 79-participant average among 6 other Hypophosphatasia trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06079359, a Phase 3 study of Hypophosphatasia, is active but no longer recruiting, sponsored by Alexion Pharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
30 participants
Enrollment target
20
Study locations

Study Summary

The primary purpose of this study is to evaluate the efficacy of ALXN1850 versus placebo on radiographic outcomes in pediatric participants with HPP who have not previously been treated with asfotase alfa.

Conditions Studied

Hypophosphatasia

Interventions

  • DRUG Placebo
  • DRUG ALXN1850

Study Locations (20)

Other

  • Research Site - Nedlands
  • Research Site - Parkville
  • Research Site - Brussels
  • Research Site - Brasília
  • Research Site - Porto Alegre
  • Research Site - Recife
  • Research Site - Salvador
  • Research Site - São Paulo
  • Research Site - São Paulo
  • Research Site - Beijing
  • Research Site - Guangzhou
  • Research Site - Shanghai
  • Research Site - Shenzhen
  • Research Site - Helsinki
  • Research Site - Ashkelon

Maryland

  • Research Site - Baltimore

Missouri

  • Research Site - Kansas City

North Carolina

  • Research Site - Durham

Alberta

  • Research Site - Calgary

Manitoba

  • Research Site - Winnepeg

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-05-14
Est. Completion 2028-08-24
Phase Phase 3

Sponsor

Alexion Pharmaceuticals

162 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06079359

The ClinicalTrials.gov registry entry for NCT06079359 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 79-participant average among 6 other Hypophosphatasia trials with a reported enrollment target (62% lower). The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hypophosphatasia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06079359 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, Maryland, Missouri.

Frequently Asked Questions

What is clinical trial NCT06079359 about?

NCT06079359 is a clinical study titled "Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP". The primary purpose of this study is to evaluate the efficacy of ALXN1850 versus placebo on radiographic outcomes in pediatric participants with HPP who have not previously been treated with asfotase alfa.

What is the current status of trial NCT06079359?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2024-05-14. Estimated completion is 2028-08-24.

What conditions does trial NCT06079359 study?

This clinical trial studies the following conditions: Hypophosphatasia.

What interventions are being tested in trial NCT06079359?

The interventions under investigation include: Placebo (DRUG), ALXN1850 (DRUG).

Who is sponsoring clinical trial NCT06079359?

This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06079359 being conducted?

This trial has 20 study locations across Maryland, Missouri, North Carolina, Alberta, Manitoba. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hypophosphatasia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hypophosphatasia

All registered trials for this condition

Maryland

All trials with a study site in Maryland

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.